cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.11897331
title: Supplementary Material for: Spinal Cord Stimulation with Surgical Lead Improves Pain and Gait in Parkinson’s Disease after a Dislocation of Percutaneous Lead: A Case Report

description: Spinal cord stimulation (SCS) is receiving increasing interests for treating pain and gait disorders in patients with Parkinson’s disease (PD). In an SCS study, it is hard to apply a double-blind approach, especially at low frequencies, as the stimulation normally induces paresthesia which can be perceived by the patient. We herein demonstrate a case treated with SCS in which a blinding design was accomplished by an accidental dislocation of a stimulation lead. A 73-year-old man with PD was admitted to our hospital because of relapsed low back pain. This was due to the dislocation of a previously implanted SCS lead, which caused a decrease in its effectiveness in alleviating pain (from 81 to 43% measured by King’s Parkinson’s Disease Pain Scale) and improving gait (from 35 to 28% measured by the timed up and go test). A second SCS surgery using a paddle lead solved this problem, with improvements in pain and gait rebounded to 81 and 45%. In this case, the paresthesia induced by SCS (using either a paddle lead or percutaneous leads) was below the threshold of perception when the patient was sitting and standing, and a dislocation of one previously implanted percutaneous lead did not cause evident changes in his sensation of paresthesia. At last follow-up, the patient’s quality of life had improved by 40% as measured by the 8-item Parkinson’s Disease questionnaire (PDQ-8). This study could serve partly as a proof that low-frequency SCS is effective in improving pain as well as gait problems in PD patients, which was unlikely a result of a placebo effect.
DOI: 10.6084/m9.figshare.11897334.v1
title: Table S1 - Melanin Pathway

description: A. fulminans blast results to check the presence/absence of genes related with the melanin degradation.<br>
DOI: 10.6084/m9.figshare.11897325
title: Supplementary Material for: Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma

description: <b><i>Background and Aims:</i></b> Combining anti-angiogenic therapy with immune checkpoint blockade with anti-programmed cell death-1 (PD-1) antibodies is a promising treatment for hepatocellular carcinoma (HCC). Tyrosine kinase inhibitors are well-known anti-angiogenic agents and offer potential for combination with anti-PD-1 antibodies. This study investigated the possible underlying immunomodulatory mechanisms of combined therapy. <b><i>Methods:</i></b> HCC tissue samples for RNA-sequencing (RNA-seq) were obtained from patients with differential prognoses following anti-PD-1 treatment. Recombinant basic fibroblast growth factor (bFGF) and vascular endothelial growth factor A (VEGFA) were used to stimulate T cells following lenvatinib or sorafenib treatment, respectively. T cell function was analyzed by flow cytometry and lactate dehydrogenase assay. In vivo experiments were conducted in murine H22 and Hepa 1–6 competent models of HCC. Local immune infiltration in the tumor microenvironment (TME) was assessed using multicolor flow cytometry. Gene regulation was evaluated by RNA-seq. Microvascular density was measured by immunohistochemistry, and PD-1 ligand (PD-L1) induction was quantified by western blot. <b><i>Results:</i></b> The baseline expression of VEGF and fibroblast growth factor (FGF) in patients with progressive disease was significantly higher than in patients achieving stable disease following anti-PD-1 treatment. VEGFA and bFGF significantly upregulated the expression of PD-1, cytotoxic T-lymphocyte-associated protein-4, and Tim-3 on T cells, while inhibiting the secretion of interferon gamma (IFNG) and granzyme B and suppressing T cell cytotoxicity. This immunosuppressive effect was reverted by lenvatinib but not sorafenib. Furthermore, dual lenvatinib/anti-PD-1 antibody therapy led to better antitumor effects than either sorafenib or fibroblast growth factor receptor (FGFR) inhibitor (BGJ398) in H22 murine models of HCC. Combined lenvatinib/anti-PD-1 treatment also led to long-term immune memory formation, while synergistically modulating the TME and enhancing the cytotoxic effect of T cells. Finally, lenvatinib inhibited PD-L1 expression on human umbilical vein endothelial cells, which improved the function of T cells. <b><i>Conclusions:</i></b> Inhibition of vascular endothelial growth factor receptor and FGFR augmented the efficacy of anti-PD-1 antibodies. Combined lenvatinib/anti-PD-1 treatment appears to exert antitumor activity by synergistically modulating effector T cell function in the TME and by mutually regulating tumor vessel normalization.
DOI: 10.6084/m9.figshare.11897331.v1
title: Supplementary Material for: Spinal Cord Stimulation with Surgical Lead Improves Pain and Gait in Parkinson’s Disease after a Dislocation of Percutaneous Lead: A Case Report

description: Spinal cord stimulation (SCS) is receiving increasing interests for treating pain and gait disorders in patients with Parkinson’s disease (PD). In an SCS study, it is hard to apply a double-blind approach, especially at low frequencies, as the stimulation normally induces paresthesia which can be perceived by the patient. We herein demonstrate a case treated with SCS in which a blinding design was accomplished by an accidental dislocation of a stimulation lead. A 73-year-old man with PD was admitted to our hospital because of relapsed low back pain. This was due to the dislocation of a previously implanted SCS lead, which caused a decrease in its effectiveness in alleviating pain (from 81 to 43% measured by King’s Parkinson’s Disease Pain Scale) and improving gait (from 35 to 28% measured by the timed up and go test). A second SCS surgery using a paddle lead solved this problem, with improvements in pain and gait rebounded to 81 and 45%. In this case, the paresthesia induced by SCS (using either a paddle lead or percutaneous leads) was below the threshold of perception when the patient was sitting and standing, and a dislocation of one previously implanted percutaneous lead did not cause evident changes in his sensation of paresthesia. At last follow-up, the patient’s quality of life had improved by 40% as measured by the 8-item Parkinson’s Disease questionnaire (PDQ-8). This study could serve partly as a proof that low-frequency SCS is effective in improving pain as well as gait problems in PD patients, which was unlikely a result of a placebo effect.
DOI: 10.6084/m9.figshare.11897301
title: Singapore Chinese LTL meta-analysis including allele frequency

description: Leukocyte telomere length GWAS meta-analysis GWAS results from Singapore Chinese subjects. Data includes rsid, chr, pos, other_allele, test_allele, meta_p, beta, se, p_het and testallelefreq
DOI: 10.6084/m9.figshare.11897310
title: Supplementary Material for: The Effect of Drug-Eluting Stents on Target Lesion Revascularization in Native Coronary Arteries: Results from the NORSTENT Randomized Study

description: <b><i>Background:</i></b> The NORSTENT trial randomized 9,013 patients to percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) or bare-metal stent (BMS) with 5-year follow-up. No difference was found in the composite primary outcome of death from any cause and nonfatal spontaneous myocardial infarction after a median of 5 years of follow-up. Secondary outcomes included repeat revascularizations, which were reduced by DES. We report the occurrence of target lesion revascularization (TLR) in time and across demographic and clinical subgroups in patients with lesions in native coronary arteries (<i>n</i> = 8,782). <b><i>Results:</i></b> Clinically driven TLR was performed on 488 (5.6%) of the 8,782 patients during 5 years of follow-up. Male gender, older age, visible thrombus in the lesion, and larger stent diameter were associated with less TLR; multivessel disease and longer stents were associated with a higher risk of TLR. There was a substantial and highly significant reduction of the risk of any TLR after 5 years in the DES group (hazard ratio [HR] 0.44, 95% confidence interval [CI] 0.36–0.52], <i>p</i> &lt; 0.001). The effect of DES on TLR was limited in time to the first 2 years in the study with no evidence of a later rebound effect. The reduction in TLR after DES insertion was consistent across subgroups defined by gender, age, diabetes status, renal function, and lesion and stent characteristics. The number needed to treat with DES (vs. BMS) to prevent 1 TLR ranged from 4 to 110 across clinically relevant subgroups. <b><i>Conclusion:</i></b> DES have a time-limited effect on the rate of TLR, but with a substantial and highly significant reduction in the first 2 years after the procedure. This effect was found to be consistent across all important clinical subgroups.
DOI: 10.6084/m9.figshare.11897301.v1
title: Singapore Chinese LTL meta-analysis including allele frequency

description: Leukocyte telomere length GWAS meta-analysis GWAS results from Singapore Chinese subjects. Data includes rsid, chr, pos, other_allele, test_allele, meta_p, beta, se, p_het and testallelefreq
DOI: 10.6084/m9.figshare.11897310.v1
title: Supplementary Material for: The Effect of Drug-Eluting Stents on Target Lesion Revascularization in Native Coronary Arteries: Results from the NORSTENT Randomized Study

description: <b><i>Background:</i></b> The NORSTENT trial randomized 9,013 patients to percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) or bare-metal stent (BMS) with 5-year follow-up. No difference was found in the composite primary outcome of death from any cause and nonfatal spontaneous myocardial infarction after a median of 5 years of follow-up. Secondary outcomes included repeat revascularizations, which were reduced by DES. We report the occurrence of target lesion revascularization (TLR) in time and across demographic and clinical subgroups in patients with lesions in native coronary arteries (<i>n</i> = 8,782). <b><i>Results:</i></b> Clinically driven TLR was performed on 488 (5.6%) of the 8,782 patients during 5 years of follow-up. Male gender, older age, visible thrombus in the lesion, and larger stent diameter were associated with less TLR; multivessel disease and longer stents were associated with a higher risk of TLR. There was a substantial and highly significant reduction of the risk of any TLR after 5 years in the DES group (hazard ratio [HR] 0.44, 95% confidence interval [CI] 0.36–0.52], <i>p</i> &lt; 0.001). The effect of DES on TLR was limited in time to the first 2 years in the study with no evidence of a later rebound effect. The reduction in TLR after DES insertion was consistent across subgroups defined by gender, age, diabetes status, renal function, and lesion and stent characteristics. The number needed to treat with DES (vs. BMS) to prevent 1 TLR ranged from 4 to 110 across clinically relevant subgroups. <b><i>Conclusion:</i></b> DES have a time-limited effect on the rate of TLR, but with a substantial and highly significant reduction in the first 2 years after the procedure. This effect was found to be consistent across all important clinical subgroups.
DOI: 10.6084/m9.figshare.11897283
title: Leptin promotes the fat preference associated with low-temperature acclimation in mice

description: Although fluctuations in energy metabolism are known to influence intake as well as nutrient selection, there are no definitive reports on how food preferences change with changes in habitat temperature. We investigated the effects of habitat temperature on appetite and food preference and elucidated the underlying mechanism by conducting a feeding experiment and a leptin administration test on mice reared at low temperatures. Our results showed that the increased food intake and HFD preference observed in the 10°C group were induced by decrease in plasma leptin concentration. Then, a leptin administration experiment was conducted to clarify the relationship between leptin and food preference with low-temperature acclimation. The control group reared in 10°C significantly preferred the HFD, but the leptin-administered group did not. These results show that the peripheral system appetite-regulating hormone leptin not only acts to suppress appetite but also might inhibit preference for lipids in low-temperature acclimation. Preference for HFD disappeared under higher temperatures. Injection of leptin suppressed the preference for HFD at lower temperatures.
DOI: 10.6084/m9.figshare.11897283.v1
title: Leptin promotes the fat preference associated with low-temperature acclimation in mice

description: Although fluctuations in energy metabolism are known to influence intake as well as nutrient selection, there are no definitive reports on how food preferences change with changes in habitat temperature. We investigated the effects of habitat temperature on appetite and food preference and elucidated the underlying mechanism by conducting a feeding experiment and a leptin administration test on mice reared at low temperatures. Our results showed that the increased food intake and HFD preference observed in the 10°C group were induced by decrease in plasma leptin concentration. Then, a leptin administration experiment was conducted to clarify the relationship between leptin and food preference with low-temperature acclimation. The control group reared in 10°C significantly preferred the HFD, but the leptin-administered group did not. These results show that the peripheral system appetite-regulating hormone leptin not only acts to suppress appetite but also might inhibit preference for lipids in low-temperature acclimation. Preference for HFD disappeared under higher temperatures. Injection of leptin suppressed the preference for HFD at lower temperatures.
DOI: 10.6084/m9.figshare.11897262
title: Simulated spectrum peak wave period (3-hourly, 2015.01-2100.12) from FIO-ESM v2.0 ssp126 experiment r1i1p1f1

description: Simulated spectrum peak wave period (3-hourly, 2015.01-2100.12) from FIO-ESM v2.0 ssp126 experiment (one of future scenarios) r1i1p1f1. The grid, named gx1v6, is the displaced pole (the North Pole displaced to the Greenland) grid with 1.1 degree in longitude and 0.27-0.54 degree in latitude.
DOI: 10.6084/m9.figshare.11897235
title: Experiment 3: Key from False holes as camouflage

description: Key to data from Costello et al. Experiment 3
DOI: 10.6084/m9.figshare.11897229
title: Experiment 1: Key from False holes as camouflage

description: Key to data from Costello et al. Experiment 1
DOI: 10.6084/m9.figshare.11897232
title: Experiment 2: Data from False holes as camouflage

description: Raw data from Costello et al. Experiment 2
DOI: 10.6084/m9.figshare.11897232.v1
title: Experiment 2: Data from False holes as camouflage

description: Raw data from Costello et al. Experiment 2
DOI: 10.6084/m9.figshare.11897235.v1
title: Experiment 3: Key from False holes as camouflage

description: Key to data from Costello et al. Experiment 3
DOI: 10.6084/m9.figshare.11897223
title: Experiment 1: Data from False holes as camouflage

description: Raw data from Costello et al. Experiment 1
DOI: 10.6084/m9.figshare.11897226
title: Experiment 2: Key from False holes as camouflage

description: Key to data from Costello et al. Experiment 2
DOI: 10.6084/m9.figshare.11897229.v1
title: Experiment 1: Key from False holes as camouflage

description: Key to data from Costello et al. Experiment 1
DOI: 10.6084/m9.figshare.11897220
title: Experiment 3: Data from False holes as camouflage

description: Raw data from Costello et al. Experiment 3
DOI: 10.6084/m9.figshare.11897226.v1
title: Experiment 2: Key from False holes as camouflage

description: Key to data from Costello et al. Experiment 2
DOI: 10.6084/m9.figshare.11897223.v1
title: Experiment 1: Data from False holes as camouflage

description: Raw data from Costello et al. Experiment 1
DOI: 10.6084/m9.figshare.11897196
title: DNA barcoding for species and diversity analyses on invasive and native dichotomous Codium species in the central area of the Cantabrian Sea, southern Bay of Biscay.

description: The excel table with designed primers and fasta. file with raw alignment used to designe those primer are available.
DOI: 10.6084/m9.figshare.11897196.v1
title: DNA barcoding for species and diversity analyses on invasive and native dichotomous Codium species in the central area of the Cantabrian Sea, southern Bay of Biscay.

description: The excel table with designed primers and fasta. file with raw alignment used to designe those primer are available.
DOI: 10.6084/m9.figshare.11897187
title: Dresden Vocal Tract Dataset (complete archive)

description: The zip-file contains the whole dataset.
DOI: 10.6084/m9.figshare.11897187.v1
title: Dresden Vocal Tract Dataset (complete archive)

description: The zip-file contains the whole dataset.
DOI: 10.6084/m9.figshare.11897175
title: Supplementary Material for: Morphometric Features of Patent Foramen Ovale as a Risk Factor of Cerebrovascular Accidents: A Systematic Review and Meta-Analysis

description: <b><i>Introduction:</i></b> It is still disputable whether specific morphometric features of the patent foramen ovale (PFO) may stratify patients by the related probability that a discovered PFO is incidental or stroke related. <b><i>Objective:</i></b> We aimed to determine whether certain morphometrical characteristics of PFO are associated with an increased risk of cerebrovascular accidents, using a meta-analytical approach. <b><i>Methods:</i></b> We performed a systematic review of electronic databases for studies that compared morphometric parameters of PFO assessed by transesophageal echocardiography (TEE) in subjects with cryptogenic cerebrovascular accidents (Group 1) and control (Group 2). Data were extracted and pooled into a meta-analysis. <b><i>Results:</i></b> A total of 895 patients with PFO were reported (Group 1: 493, Group 2: 402). No difference was found in the PFO channel length (Group 1: 10.8 [8.6–12.9] mm vs. Group 2: 10.4 [9.1–11.7] mm), as well as in PFO height measured at rest (Group 1: 2.4 [1.5–3.3] mm vs. Group 2: 1.8 [1.4–2.2] mm). The PFO height measured during a Valsalva maneuver was larger in Group 1 (3.5 [2.8–4.1] mm) than in Group 2 (1.7 [1.2–2.2] mm). Also, the septal excursion distance was found to be larger in Group 1 (6.4 [5.1–7.8] mm) than in Group 2 (3.1 [1.8–4.4] mm). The risk of cerebrovascular accident was higher in patients with PFO and concomitant septal aneurysm (OR 4.00; 95% CI 2.63–6.09; <i>p</i> &lt; 0.001) and with large right-to-left shunt PFO (OR 3.81; 95% CI 2.21–6.55; <i>p</i> &lt; 0.001), no such relationship was found for the presence of a Eustachian valve or Chiari’s network (OR 1.90; 95% CI 0.90–4.05; <i>p</i> = 0.094). <b><i>Conclusions:</i></b> The TEE may help in identifying PFO that are of high risk of cerebrovascular accident. Greater PFO height during a Valsalva maneuver, larger septal excursion distance, concomitant atrial septal aneurysm, and large right-to-left shunt are associated with stroke-related PFOs.
DOI: 10.6084/m9.figshare.11897175.v1
title: Supplementary Material for: Morphometric Features of Patent Foramen Ovale as a Risk Factor of Cerebrovascular Accidents: A Systematic Review and Meta-Analysis

description: <b><i>Introduction:</i></b> It is still disputable whether specific morphometric features of the patent foramen ovale (PFO) may stratify patients by the related probability that a discovered PFO is incidental or stroke related. <b><i>Objective:</i></b> We aimed to determine whether certain morphometrical characteristics of PFO are associated with an increased risk of cerebrovascular accidents, using a meta-analytical approach. <b><i>Methods:</i></b> We performed a systematic review of electronic databases for studies that compared morphometric parameters of PFO assessed by transesophageal echocardiography (TEE) in subjects with cryptogenic cerebrovascular accidents (Group 1) and control (Group 2). Data were extracted and pooled into a meta-analysis. <b><i>Results:</i></b> A total of 895 patients with PFO were reported (Group 1: 493, Group 2: 402). No difference was found in the PFO channel length (Group 1: 10.8 [8.6–12.9] mm vs. Group 2: 10.4 [9.1–11.7] mm), as well as in PFO height measured at rest (Group 1: 2.4 [1.5–3.3] mm vs. Group 2: 1.8 [1.4–2.2] mm). The PFO height measured during a Valsalva maneuver was larger in Group 1 (3.5 [2.8–4.1] mm) than in Group 2 (1.7 [1.2–2.2] mm). Also, the septal excursion distance was found to be larger in Group 1 (6.4 [5.1–7.8] mm) than in Group 2 (3.1 [1.8–4.4] mm). The risk of cerebrovascular accident was higher in patients with PFO and concomitant septal aneurysm (OR 4.00; 95% CI 2.63–6.09; <i>p</i> &lt; 0.001) and with large right-to-left shunt PFO (OR 3.81; 95% CI 2.21–6.55; <i>p</i> &lt; 0.001), no such relationship was found for the presence of a Eustachian valve or Chiari’s network (OR 1.90; 95% CI 0.90–4.05; <i>p</i> = 0.094). <b><i>Conclusions:</i></b> The TEE may help in identifying PFO that are of high risk of cerebrovascular accident. Greater PFO height during a Valsalva maneuver, larger septal excursion distance, concomitant atrial septal aneurysm, and large right-to-left shunt are associated with stroke-related PFOs.
DOI: 10.6084/m9.figshare.11897169
title: Supplementary Material for: Accelerated Venovenous Hemofiltration as a Transitional Renal Replacement Therapy in the Intensive Care Unit

description: <b><i>Background:</i></b> Continuous renal replacement therapy (CRRT) is commonly employed in the intensive care unit (ICU), though there are no guidelines around the transition between CRRT and intermittent hemodialysis (iHD). Accelerated venovenous hemofiltration (AVVH) is a modality utilizing higher hemofiltration rates (4–5 L/h) with shorter session durations (8–10 h) to “accelerate” the clearance and volume removal that normally is spread out over a 24-h period in CRRT. We examined AVVH as a transition therapy between CRRT and iHD, with the aim of decreasing time on CRRT and providing a more graduated transition for hemodynamically unstable patients requiring RRT. <b><i>Methods:</i></b> Retrospective cohort study describing the clinical outcomes and quality initiative experience of the integration of AVVH into the CRRT program at an academic tertiary care center. Outcomes of interest included mortality, ICU length of stay and readmission rates, and technical characteristics of treatments. <b><i>Results:</i></b> In total, 97 patients received a total of 298 AVVH treatments (3.1 ± 3.3 treatments per patient). Totally, 271/298 (91%) treatments were completed successfully. During an average treatment time of 9.5 ± 1.6 h with 4.2 ± 0.5 L/h ­replacement fluid rate, urea reduction ratio was 23 ± 26% per 10-h treatment, and net ultrafiltration volume was 2.4 ± 1.3 L/treatment. Inpatient mortality was 32%, mean total hospital length of stay was 54 ± 47 days. Sixty-four out of 97 (66%) patients recovered renal function by discharge. Among those who transferred out of the ICU, 7/62 (11%) patients required readmission to the ICU after developing hypotension on iHD. <b><i>Conclusion:</i></b> AVVH can serve as a transition therapy between CRRT and iHD in the ICU and has the potential to decrease total time on CRRT, improve patient mobility, and sustain low ICU readmission rates. Future study is needed to analyze the implications on resource use and cost of this modality.
DOI: 10.6084/m9.figshare.11897166
title: Phylogenetic Tree Raw

description: The Raw file contain alignment fasta sequence with their phylogenetic analysis
DOI: 10.6084/m9.figshare.11897166.v1
title: Phylogenetic Tree Raw

description: The Raw file contain alignment fasta sequence with their phylogenetic analysis